Abstract. Gene therapy for congenital protein deficiencies requires lifelong expression of a deficient protein. Current gene therapy approaches preferentially employ the strong cytomegalovirus (CMV) promoter/enhancer or its derivative CAG promoter; however, these promoters provide only temporary transgene expression. To create a promoter that enables long-lasting expression in muscle, hybrid promoters were constructed by coupling the muscle creatine kinase (MCK) enhancer to various strong promoters for enhancement of tissue specificity and improved transcriptional activity. A hybrid promoter containing the MCK enhancer and the simian virus 40 promoter (MCK/SV40 promoter) yielded long-term (>6 months) expression of a human secretory alkaline phosphatase (huSEAP) reporter gene following electrotransfer of the plasmid into mice, whereas expression using a conventional CMV or CAG promoter faded away within a few weeks. To explore the mechanism behind the sustained expression obtained with the MCK/SV40 promoter, mice were immunized with a LacZ expression plasmid driven by MCK/SV40 or a conventional promoter. Minimal cellular and humoral responses to LacZ were observed in MCK/SV40 promotertreated animals, and mouse SEAP gene expression in vivo was successfully maintained by both the MCK/SV40 and conventional promoters. These results suggest that the lower immunogenicity of the MCK/SV40 promoter contributed to long-lasting gene expression in mice. Therefore, the MCK/ SV40 promoter may provide the basis for development of an effective transgene expression cassette for treatment of congenital protein deficiencies in which therapeutic proteins are recognized as foreign by the host immune system.
Introduction
Skeletal muscle is easily accessible and readily expresses a transgene product; therefore, this muscle has been used as a platform for experimental gene therapy (1, 2) . Muscle-targeted gene transfer has progressed rapidly from the pioneering demonstration of reporter gene expression by Wolff et al (3) to the production of various therapeutic proteins, including clotting factors (4), erythropoietin (5, 6) , dystrophins (7), hormones (8) , and enzymes responsible for lysosomal storage diseases (9) . Such studies have shed new light on the treatment of genetic disorders; however, failure of persistence of gene expression hampers efforts towards the cure of these diseases, most of which require a lifelong supplement of the deficient protein.
The cytomegalovirus (CMV) immediate early gene promoter/enhancer (hereafter referred to as the CMV promoter) (10) or its derivative CAG promoter (11) has been used widely as a particularly powerful promoter for gene therapy, as well as for delivery of gene-mediated vaccines. Although the CMV promoter drives strong expression of the transgenes, it becomes silent within a few weeks of in vivo gene transfer (12, 13) . In most cases, expression from the CMV promoter peaks 2 to 4 days after delivery of the transgene and declines to the background level within 4 weeks (14) (15) (16) . This may be due to immunological elimination of cells bearing a foreign gene product (14, 17) , since administration of neutralizing antibodies to transgene products (18) (19) (20) also results in such transgene silencing. Thus, the success of long-term gene therapy in part depends upon the ability of the promoter to avoid induction of immune responses to the transgene product.
Use of muscle-specific promoters is a promising strategy to suppress immunogenicity of transgenes (21, 22) , since such tissue-specific promoters are inert in antigen presenting cells (APCs), whereas ubiquitous promoters such as CMV and CAG are active in these cells (23) . However, a primary drawback of tissue-specific promoters is their relatively low potential for transcriptional activity compared with ubiquitous promoters. To improve the performance of muscle-specific promoters while retaining tissue specificity, we have constructed hybrid promoters by coupling the muscle creatine kinase (MCK) enhancer to various strong promoters. The combination of the MCK enhancer and the simian virus 40 promoter (MCK/SV40
Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression promoter) achieved long-term transgene expression following intramuscular electrotransfer, while inducing only marginal levels of cellular and humoral immune responses to transgene products. Our results suggest that the MCK/SV40 promoter is a promising substitute for conventional CMV-based promoters when long-term transgene expression in the muscle is required.
Materials and methods
Plasmid construction and preparation. Plasmid construction was based on the plasmid pGA (24) , which consists of the CMV promoter plus intron A, bovine growth hormone terminator, Kan r , and pUC ori. Schematic diagrams of the promoters characterized in this study are shown in Fig. 1 . The mouse MCK promoter (nucleotides -1256 to +7; GeneBank accession no. AF188002) was PCR-amplified from genomic DNA from RAW264.7 cells using the primer pair 5'-GAC TAG TCC ACT ACG GGT CTA GGC TGC CC-3' and 5'-CCC AAG CTT GGG GGC AGC CCC TGT GCC CCT GGG-3'. The CMV promoter plus intron A in pGA was released by digestion with SpeI and HindIII and replaced with the SpeI-HindIII MCK promoter amplicon. Similarly, the SpeI-EcoRI CAG promoter fragment was excised from the pCAGGS vector (11) and substituted for the CMV promoter plus intron A, resulting in the pGA-CAG vector. To create a series of hybrid promoters, the MCK promoter containing an enhancer region (25) and another promoter were coupled by ligation. The SV40 promoter was excised from the pGL3-control vector (Promega, Madison, WI) with SmaI and HindIII or NheI and HindIII. The pGA-MCK vector was digested with SmaI and HindIII or NheI and HindIII, and then ligated with the SmaI-HindIII or NheI-HindIII SV40 promoter fragment, respectively. The ligation products contained a hybrid promoter consisting of the MCK enhancer and SV40 promoter and were designated as pGA-MCK/SV40 (L) and pGA-MCK/SV40 (S), respectively. The CMV enhancer in pGA-CAG was replaced with the SpeI-SmaI MCK fragment carrying an enhancer region to create the plasmid pGA-MCK/ß-actin, which contains a hybrid promoter comprising the MCK enhancer and chicken ß-actin promoter. Similarly, the CMV enhancer in the pGA vector was replaced with the MCK enhancer to generate pGA-MCK/CMV, which contains a hybrid promoter consisting of the MCK enhancer and CMV promoter. The reporter genes, firefly luciferase (luc) from pGL3-control, ß-galactosidase (LacZ) from pSV-ß-galactosidase (both from Promega), human secretory alkaline phosphatase (huSEAP) from pSEAP2-Basic (BD-Clontech, Palo Alto, CA), and mouse SEAP, which was cloned as described previously (26) , were subcloned into vectors containing each specific promoter. All plasmids were produced by growing transformed E. coli DH5· in LB media and then purified on Qiagen DNA purification columns (Qiagen, Hilden, Germany).
Transfection and luciferase assay. Human embryonic kidney 293 cells or mouse myoblast C2C12 cells were cultured in high-glucose DMEM supplemented with 10% FCS. The cells were seeded in 96-well tissue culture plates and grown until 50-70% confluency. They were then transiently transfected with each luciferase reporter plasmid using FuGene 6 transfection reagent (Roche, Mannheim, Germany). Two days after transfection, the luminescence signal was measured using a microplate luminometer (Veritas, Turner Biosystems, Sunnyvale, CA) with a Dual-Glo luciferase assay kit (Promega) according to the manufacturer's instructions. phRL-TK expressing Renilla luciferase (Promega) was used as a secondary reporter vector for normalization of firefly reporter activity.
Animal treatment and measurement of plasma SEAP activity.
Female BALB/c mice were purchased from Japan SLC Inc. (Shizuoka, Japan) and housed in the animal facility of Yokohama City University Graduate School of Medicine. DNA injection, electroporation, and retro-orbital puncture for blood sampling were all performed under anaesthesia produced by subcutaneous injection of a 4:1 mixture of ketamine and xylazine. Animal experiments were conducted under the approval of the institutional laboratory animal care and use committee. For electroporation, the quadriceps femoris muscles were exposed and injected with the indicated dose of plasmid in saline with a 30-gauge needle inserted 2-3 mm deep, and then the entire muscle bundle was pinched by a pair of disktype platinum electrodes (diameter: 10 mm, separation: ~5 mm; CUY650-10, Nepa Gene, Chiba, Japan). Six electrical pulses were applied at 30 V using a square wave electroporator CUY21EDIT (Nepa Gene) with a pulse duration of 50 ms, a pulse interval of 100 ms, and reversal of polarity after three pulses. This procedure was completed by closure of the incision with surgical wound clips. For hydrodynamics-based transfection to the liver (27), 10 μg of each plasmid was formulated with a polymer (Trans-IT in vivo transfection reagent, Mirus, Madison, WI) and dissolved with Ringer's solution. The DNA/polymer complex solution (2.5 ml) was injected into the tail vein of each mouse over 6-8 sec using a 27-gauge needle. Scheduled blood samples were taken by retro-orbital puncture and stored at -20˚C. Plasma SEAP activity was measured using a SEAP reporter gene chemiluminescent assay kit (Roche) and a microplate luminescence reader according to the manufacturer's instructions.
CTL assay. Splenocytes were harvested 2 weeks after the booster immunization. The CTL isolates (effector cells) were prepared after incubation with 1 μg/ml of H-2 d -restricted LacZ class I peptide (TPHPARIGL) and 20 U/ml of IL-2 (Sigma) for 4 days at 37˚C. The target cells were mouse mastocytoma P815 cells (H-2K d ) pulsed with 1 μg/ml of H-2 d -restricted LacZ class I peptide (experimental target) or H-2 b -restricted LacZ class I peptide (DAPIYTNV, sham target). The target cells (1x10 4 ) were co-cultured with the effector cells for 4 h. The amount of lactate dehydrogenase (LDH) released from the target cells was measured using a Cytotox 96 system (Promega) and % specific lysis was calculated according to the manufacturer's protocol.
ELISA. The serum Ab titer was measured by ELISA, as described elsewhere (24) .
Statistics. Statistical analysis was conducted with Student's t-test using StatView J-4.02 software (Abacus Concepts, Berkeley, CA), and significance was defined as p<0.05.
Results
In vitro characterization of the hybrid promoters. To optimize the promoter for muscle-targeting gene therapy vectors, various hybrid promoters comprising the MCK enhancer and the SV40, CMV or CAG (ß-actin) promoter were constructed as shown in Fig. 1 . Promoter activity was tested in vitro using HEK 293 (embryonal kidney) cells and C2C12 (myoblast) cells (Fig. 2) . As shown in Fig. 2A , the promoter activities of MCK and MCK/SV40 (S) were similar to that of the control (luc w/o promoter) in HEK 293 cells, whereas conventional CMV and CAG promoters exhibited robust activities. Among the hybrid promoters, the MCK/CMV promoter showed the best performance, reaching approximately one-tenth of the expression level obtained under control of the CMV or CAG promoter. In contrast, MCK and the hybrid promoters yielded substantial reporter gene expression in C2C12 cells (Fig. 2B ) and the MCK/CMV (L) promoter showed the best performance among the hybrids, suggesting that the activities of the MCK promoter and derivatives are higher in myoblasts than in non-muscle cells. Based upon the good performance in C2C12 cells, MCK/SV40 (L), MCK/CMV and MCK/ß-actin promoters were used for in vivo characterization.
In vivo characterization of hybrid promoters. We next examined whether the hybrid promoters increased transgene expression in mouse muscle, using a human placental secretory alkaline phosphatase (huSEAP) reporter gene. SEAP activity can be monitored in a plasma-based assay that allows longterm surveillance of the gene expression profile without sacrificing the animals. We chose the human gene, and not mouse SEAP, due to the immunogenicity of human SEAP in mice (28, 29) ; this protocol mimics the conditions in gene therapy for congenital protein deficiencies, since proteins responsible for congenital deficiencies are often recognized as foreign by the immune system (30) (31) (32) . SEAP expression profiles in mice that received intramuscular electrotransfer of a human SEAP expression plasmid are shown in Fig. 3 . It is clear that only the MCK/SV40 (L) promoter maintained SEAP activity after 4 weeks, whereas expression with other promoters declined rapidly to the background level. Prolonged monitoring was used to test the long-term sustainability of huSEAP expression under control of the MCK/SV40 (L) promoter, as shown in Fig. 3B . The MCK/SV40 (L) promoter was able to sustain SEAP expression for 29 weeks, whereas expression with the control CMV promoter decreased to below the background level within 4 weeks. These findings suggest that the MCK/SV40 (L) promoter is a promising substitute for the conventional CMV promoter when longterm expression is required for immunogenic transgene products.
Immunogenicity of the MCK/SV40 (L) promoter.
Immunemediated elimination of cells bearing a transgene product (14, 17) and neutralizing antibodies to transgene products (18) (19) (20) might account for the transient expression observed with conventional CMV and CAG promoters. Thus, the above results suggest that the MCK/SV40 (L) promoter has weak immunogenicity, which allows long-term transgene expression. To assess the immunogenic properties of the MCK/SV40 (L) promoter, LacZ expression plasmids driven by the MCK/SV40 (L), CAG, and CMV promoters were constructed and administered to mice. The LacZ-specific cytotoxic T-lymphocyte (CTL) activity of splenocytes from mice immunized with each plasmid is shown in Fig. 4 . It is noteworthy that both the CAG and CMV promoters elicited considerable lytic activity, whereas the activity elicited by the MCK/SV40 (L) promoter remained at a background level. Similar results were observed when humoral immune responses were examined (Fig. 5 ). Immunization with a plasmid containing CAG or CMV promoter resulted in substantial antibody production after 6 weeks, with the CAG promoter producing more antibodies than the CMV promoter, as reported previously (33) . The MCK/SV40 (L) promoter generated a minimal antibody response after 6 weeks; overall, the cellular and humoral immune responses in the presence of the MCK/SV40 (L) promoter suggest that this promoter has minimal immunogenicity. Fig. 6A . In contrast to the results for huSEAP, sustained expression of mSEAP was observed with the CMV and CAG promoters. Mouse SEAP expression with the MCK/SV40 (L) promoter was also sustainable, but the expression level was only about one-tenth that with the CMV or CAG promoter. Considering both the human and mouse SEAP expression profiles, it was concluded that intramuscular transfection of the MCK/SV40 (L) promoter allowed long-term expression of an immunogenic transgene, but that the actual promoter activity in the muscle was moderate. In contrast, conventional CMV and CAG promoters are much stronger in the muscle, but could not sustain expression of an immunogenic transgene product after intramuscular electrotransfer. To assess the tissue specificity of MCK/SV40 (L) promoter activity, mSEAP-expressing plasmids driven by a CAG, CMV or MCK/SV40 (L) promoter were transfected into the liver, using a conventional hydrodynamic method. As shown in Fig. 6B , SEAP activity with the MCK/SV40 (L) promoter was about one-hundredth of that with the conventional promoters, suggesting muscle specificity of MCK/SV40 (L) promoter activity.
Expression levels of non-immunogenic transgene products

Discussion
To examine long-term transgene expression, a hybrid MCK/ SV40 (L) promoter was generated by coupling the muscle creatine kinase enhancer to the SV40 promoter. The levels of immunogenic and non-immunogenic transgene products under control of the novel promoter were compared with those produced by conventional ubiquitous CAG and CMV promoters after intramuscular electrotransfer in mice. A key finding in the study is that the MCK/SV40 (L) promoter achieved long-term expression of an immunogenic reporter gene with minimal induction of cellular and humoral immune responses to the transgene product. Muscle has been a major target in attempts to seek effective gene therapy using plasmid vectors, because it is easily accessible and efficiently secretes the transgene product into the systemic circulation (1,2). Thus, improvement of gene expression in muscle is of importance for the progress of gene therapy for congenital disorders that can be treated with a therapeutic gene product in the circulation, such as hemophilia (34) and lysosomal storage diseases (9) . Previous studies have shown that intramuscular plasmid injection results in production of therapeutic protein in treatment of each of these diseases (16, 35) . However, the lack of persistent gene expression hampers efforts to supply therapeutic levels of gene products. In this regard, the MCK/SV40 (L) promoter might be suited for gene therapy of these and other disorders that can be treated by supplying a deficient protein in the systemic circulation.
Another concern in gene therapy for congenital disorders is elicitation of immune responses against the deficient protein, since the patient's immune system might recognize a previously unexpressed protein as foreign. In fact, production of antibodies against deficient proteins has been reported in patients undergoing enzyme replacement therapy for congenital deficiencies such as hemophilia A and B (32), adenosine deaminase deficiency (36) , mucopolysaccharidosis type I (30), Gaucher disease (37), Fabry disease (31), and Pompe disease (38) . In these patients, the antibodies may neutralize the bioactivity of the therapeutic protein; moreover, administration of the vector encoding the therapeutic protein might augment the immune response to a transgene, as seen in prime-boost immunization of DNA vaccines. Two pathways have been proposed in DNA-raised specific immune responses following intramuscular injection with DNA vaccines. APCs recruited to the muscles may take up DNA and express and process the encoding Ag for direct presentation to cognate T-and Blymphocytes (direct-priming). Alternatively, Ag proteins expressed by muscle cells may be taken up and processed by APCs and subsequently presented to Ag-specific lymphocytes (cross-priming). Moreover, reports from other groups and our previous studies have shown that direct transfection of DNA vaccines into APCs by intramuscular electroporation is responsible for subsequent immunogenicity (39) (40) (41) . Such evidence strongly suggests that the minimal immunogenicity of the MCK/SV40 promoter is due to its weak activity, especially in transfected APCs. The long-lasting expression of the huSEAP gene under the control of the MCK/SV40 (L) promoter suggests that this promoter has favorable characteristics for gene therapy targeted to congenital protein deficiencies. It will be of interest to examine the expression profiles of therapeutic genes, rather than reporter genes, using the MCK/SV40 (L) promoter to determine whether the promoter is functional in a gene therapy model. With allogeneic mSEAP as a reporter gene, SEAP expression persisted for at least 4 weeks with all tested promoters. This is in marked contrast to the rapid decrease in SEAP activity observed in huSEAP-treated animals. The difference in expression of human and mouse SEAP indicates that huSEAP clearance occurs through an immune-mediated mechanism, which is consistent with previous observations showing that the plasma huSEAP level is in inverse proportion to the anti-huSEAP antibody titer (15, 29, 42) . As noted, the strongest SEAP expression was attained with conventional promoters, and not with the MCK/SV40 (L) promoter, which might be a reflection of the net promoter activity for a nonimmunogenic reporter gene. This suggests that the MCK/ SV40 (L) promoter is unlikely to improve transgene expression for a non-immunogenic gene. However, studies of gene transfer of allogeneic factor VIII (20, 43, 44) , IX (45, 46) , and erythropoietin (19, 47) into animals indicate the risk of eliciting immune responses against a transgene, even if it originates from the same species. Thus, we believe that the MCK/SV40 (L) promoter might confer considerable benefit in gene therapy for congenital protein deficiencies in which the therapeutic gene is recognized as foreign by the immune system.
In conclusion, the novel promoter created in the current study, the MCK/SV40 (L) promoter, might be a promising substitute for conventional CMV and CAG promoters when persistent expression is required for a transgene that triggers immune responses. The current results provide the basis for further advances in muscle-targeted gene therapy for congenital protein deficiencies, and studies are now necessary to determine whether this novel promoter can achieve sustainable expression of genes associated with congenital protein deficiencies.
